{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:41:59Z","timestamp":1785526919604,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-03005-1","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:57:03Z","timestamp":1782395823000},"page":"1816-1819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events"],"prefix":"10.1038","volume":"40","author":[{"given":"Anthony G.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Phillip","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Alsouqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-1000","authenticated-orcid":false,"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1605-7875","authenticated-orcid":false,"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-6069","authenticated-orcid":false,"given":"Cecelia","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Wiczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-0082","authenticated-orcid":false,"given":"Lindsay","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6482-842X","authenticated-orcid":false,"given":"Tyler","family":"Everhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Grantier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"3005_CR1","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"3005_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391.","journal-title":"Lancet"},{"key":"3005_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213\u201323.","journal-title":"N Engl J Med"},{"key":"3005_CR4","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood.2024028205","volume":"146","author":"JA Burger","year":"2025","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Sarma A, et al. Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL. Blood. 2025;146:2168\u201376.","journal-title":"Blood"},{"key":"3005_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood.2024024476","volume":"146","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, et al. Acalabrutinib-Obinutuzumab Improves Survival vs. Chemoimmunotherapy in TN CLL in the 6-year Follow-up of ELEVATE-TN. Blood. 2025;146:1276\u201385.","journal-title":"Blood"},{"key":"3005_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"3005_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323\u201332.","journal-title":"N Engl J Med"},{"key":"3005_CR8","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128:2199\u2013205.","journal-title":"Blood"},{"key":"3005_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Detailed safety profile of acalabrutinib vs. ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142:687\u201399.","journal-title":"Blood"},{"key":"3005_CR10","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41375-021-01342-x","volume":"35","author":"AS Ruppert","year":"2021","unstructured":"Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021;35:2854\u201361.","journal-title":"Leukemia"},{"key":"3005_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320.","journal-title":"Blood"},{"key":"3005_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","volume":"394","author":"O Al-Sawaf","year":"2025","unstructured":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, et al. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. 2025;394:1084\u201396.","journal-title":"N Engl J Med"},{"key":"3005_CR13","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","volume":"129","author":"PM Barr","year":"2017","unstructured":"Barr PM, Brown JR, Hillmen P, O\u2019Brien S, Barrientos JC, Reddy NM, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL. Blood. 2017;129:2612\u20135.","journal-title":"Blood"},{"key":"3005_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00277-023-05309-z","volume":"102","author":"S Yang","year":"2023","unstructured":"Yang S, Li N, Zhu R, Feng Y, Zhuo J, Gale RP, et al. Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed\/refractory chronic lymphocytic leukemia. Ann Hematol. 2023;102:2181\u20138.","journal-title":"Ann Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03005-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:05:58Z","timestamp":1785521158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03005-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3005"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03005-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAW has consulted for AbbVie, AstraZeneca, BeOne, Genentech, Janssen, Loxo@Lilly, Merck, Newave, and Pharmacyclics. She has received research funding from AbbVie, BeOne, Janssen, Loxo@Lilly, and Schrodinger. KAR receives research finding from Genentech, AbbVie, AstraZeneca, and LOXO@Lilly and consulted for AbbVie, Genentech, BeOne, Janssen, Pharmacyclics, AstraZeneca, and Alpine Immune Science. ASK has participated in advisory boards or consulted for AbbVie, AstraZeneca, BMS, Eli Lilly, and Galapagos, and has received honoraria in relation to speaking engagements for AstraZeneca, BeOne, Eli Lilly, and Janssen. AA received research funding from BeOne. SAB has received funding from AstraZeneca and has consulted for AbbVie, AstraZeneca, BeOne, Pharmacyclics, and Genentech. All others have no conflict of interest to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved under the Ohio State University (OSU) Cancer Institutional review board (IRB).","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}